Literature DB >> 33626973

Iatrogenic Ureteral Injury Treatment with Biodegradable Antireflux Heparin-Coated Ureteral Stent-Animal Model Comparative Study.

Federico Soria1, Julia E de La Cruz1, Alberto Budia2, Marcos Cepeda3, Sara Álvarez4, Álvaro Serrano5, Francisco M Sanchez-Margallo6.   

Abstract

Objective: The aim is to assess the effectiveness of a biodegradable antireflux ureteral stent with heparin coating in a comparative study (BraidStent®-H) in an animal model for the treatment of iatrogenic ureteral perforation. Materials and
Methods: A total of 24 female pigs underwent initial endoscopic, nephrosonographic, and contrast fluoroscopy assessment of the urinary tract. Afterward, unilateral iatrogenic perforation in proximal ureter model was performed. Then the animals were randomly assigned to Group-I, in which a double-pigtail stent was placed for 6 weeks, or Group-II, in which a BraidStent-H a biodegradable heparin-coated stent was placed. Follow-up assessments were performed at 1 and 6 weeks and 5 months.
Results: In terms of therapeutic effectiveness, complete resolution was observed in 95.8% of Group-I animals and 87.5% in Group-II. No animals in Group-II showed vesicoureteral reflux (VUR) during the study; statistical significance was observed at 1 and 6 weeks versus Group-I. All stents in Group-II degraded without producing obstructive fragments and allowed distal ureteral peristalsis. Heparin coating was not efficient to reduce asymptomatic bacteriuria between groups. Pathologic assessment did not show any significance in the global score, but did in the "fibrosis in muscular layer" parameter, at the ureteral perforation healing area; Group-II showed higher healing quality. Conclusions: The biodegradable intraureteral BraidStent®-H is highly effective for the minimally invasive treatment of ureteral perforation, since it displays controlled and predictable degradation, avoiding the development of VUR as well as irritation of the bladder trigone. Unfortunately, heparin coating was not effective in avoiding stent-associated bacteriuria.

Entities:  

Keywords:  antireflux; biodegradable ureteral stent; biofilm; heparin coated; iatrogenic ureteral perforation; morbidity

Year:  2021        PMID: 33626973     DOI: 10.1089/end.2020.0591

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  5 in total

1.  Biodegradable ureteral stents: in vitro assessment of the degradation rates of braided synthetic polymers and copolymers.

Authors:  Julia E de la Cruz; María Soto; Luna Martínez-Plá; Juan Antonio Galán-Llopis; Francisco M Sánchez-Margallo; Federico Soria
Journal:  Am J Clin Exp Urol       Date:  2022-02-15

Review 2.  Urinary Stent Development and Evaluation Models: In Vitro, Ex Vivo and In Vivo-A European Network of Multidisciplinary Research to Improve Urinary Stents (ENIUS) Initiative.

Authors:  Noor Buchholz; Alberto Budia; Julia de la Cruz; Wolfgang Kram; Owen Humphreys; Meital Reches; Raquel Valero Boix; Federico Soria
Journal:  Polymers (Basel)       Date:  2022-04-19       Impact factor: 4.967

3.  10-Year Experience with Reinforced Ureteral Stents for Malignant Ureteral Obstruction.

Authors:  Benoît Vogt; Laure-Hélène Blanchet
Journal:  Res Rep Urol       Date:  2021-08-14

4.  Assessment of a Coated Mitomycin-Releasing Biodegradable Ureteral Stent as an Adjuvant Therapy in Upper Urothelial Carcinoma: A Comparative In Vitro Study.

Authors:  Federico Soria; Salvador David Aznar-Cervantes; Julia E de la Cruz; Alberto Budia; Javier Aranda; Juan Pablo Caballero; Álvaro Serrano; Francisco Miguel Sánchez Margallo
Journal:  Polymers (Basel)       Date:  2022-07-28       Impact factor: 4.967

5.  Cytotoxicity Assessment of a New Design for a Biodegradable Ureteral Mitomycin Drug-Eluting Stent in Urothelial Carcinoma Cell Culture.

Authors:  Federico Soria; Luna Martínez-Pla; Salvador D Aznar-Cervantes; Julia E de la Cruz; Tomás Fernández; Daniel Pérez-Fentes; Luis Llanes; Francisco Miguel Sánchez-Margallo
Journal:  Polymers (Basel)       Date:  2022-09-29       Impact factor: 4.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.